Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion

References

• Upadhyay A, Jaber BL, Madias NE. Epidemiology of hyponatremia. Semin. Nephrol.29(3), 227–238 (2009).
   PubMed Web of Science ®Google Scholar
• Fenske W, Allolio B. The syndrome of inappropriate secretion of antidiuretic hormone: diagnostic and therapeutic advances. Horm. Metab. Res.42(10), 691–702 (2010).
   PubMed Web of Science ®Google Scholar
• Klein L, O’Connor CM, Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation111(19), 2454–2460 (2005).
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am. J. Med.120(11A), S1–S21 (2007).
   Google Scholar
• Leaf A, Mamby AR. An antidiuretic mechanism not regulated by extracellular fluid tonicity. J. Clin. Invest.31(1), 60–71 (1952).
   PubMed Web of Science ®Google Scholar
• Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am. J. Med.42, 790–806 (1967).
   PubMed Web of Science ®Google Scholar
• Benda L, Rissel E, Stefenelli N. The effect of cortisone and desoxycorticosterone on the catabolism of the diuretic hormone of the neurohypophysis (ADH) in liver, spleen and kidney homogenates. Wien. Klin. Wochenschr.67(42), 822–824 (1955).
   PubMedGoogle Scholar
• Husain MK, Fernando N, Shapiro M, Kagan A, Glick SM. Radioimmunoassay of arginine vasopressin in human plasma. J. Clin. Endocrinol. Metab.37(4), 616–625 (1973).
   PubMed Web of Science ®Google Scholar
• Vanhees SL, Paridaens R, Vansteenkiste JF. Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review. Ann. Oncol.11(8), 1061–1065 (2000).
   PubMed Web of Science ®Google Scholar
• Miller M. Syndromes of excess antidiuretic hormone release. Crit. Care Clin.17(1), 11–23 (2001).
   PubMed Web of Science ®Google Scholar
• Casulari LA, Costa KN, Albuquerque RC, Naves LA, Suzuki K, Domingues L. Differential diagnosis and treatment of hyponatremia following pituitary surgery. J. Neurosurg. Sci.48(1), 11–18 (2004).
   PubMedGoogle Scholar
• Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am. J. Med.119(1), 71.e1–8 (2006).
   PubMedGoogle Scholar
• Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs67(6), 847–858 (2007).
   PubMed Web of Science ®Google Scholar
• Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc. Res.51, 372–390 (2001).
   PubMed Web of Science ®Google Scholar
• Goldsmith SR. Baroreceptor-mediated suppression of osmotically stimulated vasopressin in normal humans. J. Appl. Physiol.65(3), 1226–1230 (1988).
   PubMed Web of Science ®Google Scholar
• Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int.10(1), 25–37 (1976).
   PubMed Web of Science ®Google Scholar
• Schweiger TA, Zdanowicz MM. Vasopressin-receptor antagonists in heart failure. Am. J. Health Syst. Pharm.65(9), 807–817 (2008).
   PubMed Web of Science ®Google Scholar
• Jard S. Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int. Suppl.26, S38–S42 (1988).
   Google Scholar
• Xu YJ, Gopalakrishnan V. Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ. Res.69, 239–245 (1991).
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Haneda T, Osaki J et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur. J. Pharmacol.391, 39–48 (2000).
   PubMed Web of Science ®Google Scholar
• Penit J, Faure M, Jard S. Vasopressin and Ang II receptors in rat aortic smooth muscle cells in culture. Am. J. Physiol.244, E72–E82 (1983).
   PubMed Web of Science ®Google Scholar
• Nielsen S, Chou CL, Marples D et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin–CD water channels to plasma membrane. Proc. Natl Acad. Sci. USA92, 1013–1017 (1995).
   PubMed Web of Science ®Google Scholar
• Gassanov N, Jankowski M, Danalache B et al. Arginine vasopressin-mediated cardiac differentiation: insights into the role of its receptors and nitric oxide signaling. J. Biol. Chem.282(15), 11255–11265 (2007).
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol.46(10), 1785–1791 (2005).
   PubMed Web of Science ®Google Scholar
• Gassanov N, Semmo N, Semmo M, Nia AM, Fuhr U, Er F. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur. J. Clin. Pharmacol.67(4), 333–346 (2011).
   PubMed Web of Science ®Google Scholar
• Gross P. Treatment of hyponatremia. Intern. Med.47(10), 885–891 (2008).
   PubMed Web of Science ®Google Scholar
• Zietse R, van der Lubbe N, Hoorn EJ. Current and future treatment options in SIADH. NDT Plus2(Suppl. 3), iii12–iii19 (2009).
   PubMedGoogle Scholar
• Decaux G, Mols P, Cauchi P, Delwiche F. Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics. Br. Med. J.290(6484), 1782–1783 (1985).
   PubMed Web of Science ®Google Scholar
• Adrogue HJ, Madias NE. Hyponatremia. N. Engl. J. Med.342, 1581–1589 (2000).
   PubMed Web of Science ®Google Scholar
• Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N. Engl. J. Med.356, 2064–2072 (2007).
   PubMed Web of Science ®Google Scholar
• Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann. Pharmacother.37, 1694–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Rabinstein AA, Bruder N. Management of hyponatremia and volume contraction. Neurocrit. Care15(2), 354–360 (2011).
   PubMed Web of Science ®Google Scholar
• Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet371(9624), 1624–1632 (2008).
   PubMed Web of Science ®Google Scholar
• Sawyer WH, Pang PK, Seto J, McEnroe M, Lammek B, Manning M. Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science212(4490), 49–51 (1981).
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Nakamura S, Itoh S et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther.287(3), 860–867 (1998).
   PubMed Web of Science ®Google Scholar
• Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail. Rev.14, 75–82 (2009).
   PubMed Web of Science ®Google Scholar
• Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J. Clin. Pharmacol.47, 1498–1507 (2007).
   PubMed Web of Science ®Google Scholar
• Lee CR, Watkins ML, Patterson JH et al. Vasopressin: a new target for the treatment of heart failure. Am. Heart J.146, 9–18 (2003).
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Castaner J, Bayes M, Silvestre J. Tolvaptan. Drugs Fut.27(4), 350–357 (2002).
   Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA297, 1319–1331 (2007).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am. J. Cardiol.96, 68G–73G (2005).
   Web of Science ®Google Scholar
• Rangasetty UC, Gheorghiade M, Uretsky BF, Orlandi C, Barbagelata A. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Expert Opin. Investig. Drugs.15(5), 533–540 (2006).
   PubMed Web of Science ®Google Scholar
• Ambrosy A, Goldsmith SR, Gheorghiade M. Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin. Pharmacother.12(6), 961–976 (2011).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC Jr et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA297(12), 1332–1343 (2007).
   PubMed Web of Science ®Google Scholar
• Udelson JE, O’Brien T, Sequeira R et al. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination. J. Am. Coll. Cardiol.39, 810 (2002) (Abstract).
   Google Scholar
• Costello-Boerrigter LC, Smith WB, Boerrigter G et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol.290, F273–F278 (2006).
   PubMed Web of Science ®Google Scholar
• Udelson JE, Orlandi C, Ouyang J et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J. Am. Coll. Cardiol.52, 1540–1545 (2008).
   PubMed Web of Science ®Google Scholar
• Udelson JE, McGrew FA, Flores E et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol.49, 2151–2159 (2007).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gottlieb SS, Udelson JE et al. Vasopressin V(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol.97, 1064–1067 (2006).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med.355, 2099–2112 (2006).
   PubMed Web of Science ®Google Scholar
• Berl T, Quittnat-Pelletier F, Verbalis JG et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J. Am. Soc. Nephrol.21, 705–712 (2010).
   PubMed Web of Science ®Google Scholar
• Cooke CR, Turin MD, Walker WG. The syndrome of inappropriate antidiuretic hormone secretion: pathophysiologic mechanisms in solute and volume regulation. Medicine58, 240–251 (1979).
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Okada K, Saito T. Vasopressin secretion in health and disease. In: The Pituitary Gland (2nd Edition). Imura H (Ed.). Raven Press, NY, USA, ,331–350 (1994).
   Google Scholar
• Soupart A, Gross P, Legros JJ et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin. J. Am. Soc. Nephrol.1(6), 1154–1160 (2006).
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS; for the SALT Investigators. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur. J. Endocrinol.164(5), 725–732 (2011).
   PubMed Web of Science ®Google Scholar
• Saito T, Ishikawa S, Abe K et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of anti-diuretic hormone (SIADH). J. Clin. Endocrinol. Metab.82, 1054–1057 (1997).
   PubMed Web of Science ®Google Scholar
• Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am. J. Med.110, 582–584 (2001).
   PubMed Web of Science ®Google Scholar
• Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology37(1), 182–191 (2003).
   PubMed Web of Science ®Google Scholar
• Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan study group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am. J. Nephrol.27(5), 447–457 (2007).
   PubMed Web of Science ®Google Scholar
• Ghali JK, Koren MJ, Taylor JR et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab.91(6), 2145–2152 (2006).
   PubMed Web of Science ®Google Scholar
• Aronson D, Mueller M, Verbalis K, Krum H. Satavaptan, a vasopressin V2-receptor antagonist, in the treatment of dilutional hyponatremia. J. Am. Soc. Nephrol.18, 790A (2007) (Abstract).
   Google Scholar
• Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am. J. Med. Sci.337(1), 28–36 (2009).
   PubMed Web of Science ®Google Scholar
• Gross PA, Wagner A, Decaux G. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. Kidney Int.80(6), 594–600 (2011).
   PubMed Web of Science ®Google Scholar
• Velez JCQ, Dopson SJ, Sanders DS et al. Intravenous conivaptan for the treatment of hyponatremia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol. Dial. Transplant.25, 1524–1531 (2010).
   PubMed Web of Science ®Google Scholar
• Torres AC, Wickham EP, Biskobing DM. Tolvaptan for the management of SIADH: lessons learned in titration of dose. Endocr. Pract.17(4), e97–e100 (2011).
   Google Scholar
• Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am. J. Kidney Dis.56, 325–337 (2010).
   PubMed Web of Science ®Google Scholar
• Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Effect. Res. Alloc.4, 10–20 (2006).
   PubMedGoogle Scholar
• Adler SM, Verbalis JG, Ouyang J, Orlandi C, Czerwiec FS. Management of SIADH with tolvaptan: a subanalysis from the SALT trials. Presented at: American Association of Clinical Endocrinologists 16th Annual Meeting and Clinical Congress. Seattle, WA, USA, 11–15 April 2007 (Abstract 368).
   Google Scholar